Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter April 14, 2015

Head-to-head comparison of 10 natriuretic peptide assays

  • Delphine Collin-Chavagnac EMAIL logo , Monique Dehoux , François Schellenberg , Bruno Cauliez , Françoise Maupas-Schwalm , Guillaume Lefevre and on behalf of the Société Française de Biologie Clinique (SFBC) Cardiac Markers Working Group

Abstract

Background: The aim of the study was to compare NT-proBNP and BNP levels in fresh samples from heart failure (HF) patients measured using 10 immunoassays and to assess their agreement.

Methods: NT-proBNP (CobasH232®, Elecsys®, Vidas®, Vista®, XPand®, Vitros®) and BNP (Triage®, Access®, CentaurXP®, Architect®) levels were measured in 39 heparin and 19 EDTA samples, respectively.

Results: The Pearson correlation coefficient ranged between 0.929 (Triage®-Centaur®) and 0.994 (Access®-Architect®) for BNP assays and between 0.972 (Vidas®-Cobas H232®) and 0.999 (Vitros®-Vidas®) for NT-proBNP assays. Passing Bablok regression analyses showed a significant difference in the slopes [0.80 (Centaur®-Triage®) to 1.84 (Architect®-Centaur®)] and intercepts [–55 ng/L (Architect®-Centaur®) to 48 ng/L (Access®-Triage®)] for BNP assays, and a lower heterogeneity between NT-proBNP assays [0.83 (Vidas®-Elecsys®) to 1.20 (Vitros®-Vidas®) and –97 ng/L (XPand®-CobasH232®) to 51 ng/L (CobasH232®-Elecsys®) for slopes and intercepts, respectively]. The concordance correlation coefficient revealed a poor (ρc<0.90) to moderate (ρc=0.90–0.95) agreement in 4/6 pairs of BNP assays and an almost perfect (ρc>0.99) agreement in 5/15 pairs of NT-proBNP assays. The acceptable difference limit reflecting the number of individual discrepant results between two assays, ranged between 15.1% (Access®-CentaurXP®) and 34.5% (Architect®-Triage®) for BNP assays, and between 10.9% (Vidas®-Vitros®) and 55% (CobasH232®-Xpand®) for NT-proBNP assays.

Conclusions: This study stresses the lack of transferability of the results obtained using different techniques to measure BNP and NT-proBNP levels in fresh samples. Individual reference ranges and HF diagnostic cut-offs should be assessed for each commercial NP immunoassay. We recommend to systematically monitoring HF patients using the same assay (BNP or NT-proBNP) over the time.


Corresponding author: Delphine Collin-Chavagnac, Laboratoire de Biochimie et Biologie Moléculaire, Centre Hospitalier Universitaire Lyon Sud, 165 Chemin du Grand Revoyet, 69 495 Pierre Bénite Cedex, Hospices Civils de Lyon, France, Phone: +33 4 78861597, Fax: +33 4 78862198, E-mail: ; and ProBioQual, 9 rue Professeur Florence 690003, Lyon, France

Acknowledgments

The authors are indebted to the patients who participated in the study, to the cardiology department staff and the laboratory biologists and technicians for their help.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Financial support: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organisation(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Khan IA, Fink J, Nass C, Chen H, Christenson R, de Filippi CR. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol 2006;97:1530–4.10.1016/j.amjcard.2005.11.090Search in Google Scholar PubMed

2. Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006;47:345–53.10.1016/j.jacc.2005.09.025Search in Google Scholar PubMed PubMed Central

3. Rehman SU, Januzzi JL. Natriuretic peptide testing in primary care. Curr Cardiol Rev 2008;4:300–8.10.2174/157340308786349499Search in Google Scholar PubMed PubMed Central

4. Mair J, Gerda F, Renate H, Ulmer H, Andrea G, Pachinger O. Head-to-head comparison of B-type natriuretic peptide (BNP) and NT-proBNP in daily clinical practice. Int J Cardiol 2008;124:244–6.10.1016/j.ijcard.2006.11.230Search in Google Scholar PubMed

5. Giuliani I, Rieunier F, Larue C, Delagneau JF, Granier C, Pau B, et al. Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clin Chem 2006;52:1054–61.10.1373/clinchem.2005.061770Search in Google Scholar PubMed

6. Lam CS, Burnett JC Jr, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 2007;49:1193–202.10.1016/j.jacc.2006.12.024Search in Google Scholar PubMed

7. Miller WL, Phelps MA, Wood CM, Schellenberger U, Van Le A, Perichon R, et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail 2011;4:355–60.10.1161/CIRCHEARTFAILURE.110.960260Search in Google Scholar PubMed

8. Prontera C, Zucchelli GC, Vittorini S, Storti S, Emdin M, Clerico A. Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NT-proBNP. Clin Chim Acta 2009;400:70–3.10.1016/j.cca.2008.10.011Search in Google Scholar PubMed

9. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803–69.Search in Google Scholar

10. Bruins S, Fokkema MR, Römer JW, DeJongste MJ, van der Dijs FP, van den Ouweland JM, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052–8.10.1373/clinchem.2004.038752Search in Google Scholar PubMed

11. O’Hanlon R, O’Shea P, Ledwidge M, O’Loughlin C, Lange S, Conlon C, et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Cardiac Fail 2007;13:50–5.10.1016/j.cardfail.2006.09.003Search in Google Scholar PubMed

12. Rawlins ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 2005;123:439–45.10.1309/PDJ2RMM80FVRDH7WSearch in Google Scholar

13. Di Serio F, Ruggieri V, Varraso L, De Sario R, Mastrorilli A, Pansini N. Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010. Clin Chem Lab Med 2005;43:1263–73.10.1515/CCLM.2005.217Search in Google Scholar PubMed

14. Ordonez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: analytical considerations. Am J Cardiol 2008;101:9–15.10.1016/j.amjcard.2007.11.013Search in Google Scholar PubMed

15. Prontera C, Zaninotto M, Giovannini S, Zucchelli GC, Pilo A, Sciacovelli L, et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study. Clin Chem Lab Med 2009;47:762–8.10.1515/CCLM.2009.153Search in Google Scholar PubMed

16. Luckenbill KN, Christenson RH, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem 2008;54:619–21.10.1373/clinchem.2007.097998Search in Google Scholar PubMed

17. Clerico A, Zaninoto M, Prontera C, Giovannini S, Ndreu R, Franzini M, et al. Study group on Cardiovascular Risk Biomarkers of the Italian Society of Clinical Biochemistry. State of the art of BNP and NT-proBNP immunoassays: the CardioOrmocheck study. Clin Chim Acta 2012;414:112–9.10.1016/j.cca.2012.07.017Search in Google Scholar PubMed

18. Annales du Contrôle National de Qualité des Analyses de Biologie Médicale: Available from: http://ansm.sante.fr/var/ansm_site/storage/original/application/864745724deb88c48699b2b293ae8fce.pdf.Search in Google Scholar

19. Pereira M, Azevedo A, Severo M, Barros H. Long-term stability of endogenous B-type natriuretic peptide after storage at -20 degrees C or -80 degrees C. Clin Chem Lab Med 2008;46:1171–4.10.1515/CCLM.2008.223Search in Google Scholar PubMed

20. Azzazy HM, Christenson RH, Duh SH. Stability of B-type natriuretic peptide (BNP) in whole blood and plasma stored under different conditions when measured with the Biosite Triage or Beckman-Coulter Access systems. Clin Chim Acta 2007;384:176–8.10.1016/j.cca.2007.05.025Search in Google Scholar PubMed

21. Chien TI, Chen HH, Kao JT. Comparison of Abbott AxSym and Roche Elecsys 2010 for measurement of BNP and NT-proBNP. Clin Chim Acta 2006;369:95–9.10.1016/j.cca.2006.01.017Search in Google Scholar PubMed

22. McBride GB. A proposal of strength of agreement criteria for Lin’s concordance correlation coefficient: NINA Client Report 2005; HAM 2005–062.Search in Google Scholar

23. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al; ESC committee for practice guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Eur Heart J 2012;33:1787–847.10.1093/eurheartj/ehs104Search in Google Scholar PubMed

24. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part 1. J Clin Chem Clin Biochem 1983;21:709–20.Search in Google Scholar

25. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255–68.10.2307/2532051Search in Google Scholar

26. ISO 5725-6. Accuracy (trueness and precision) of measurement methods and results. Part 6: use in practice of accuracy values; 1994.Search in Google Scholar

27. Prontera C, Storti S, Emdin M, Passino C, Zyw L, Zucchelli GC, et al. Comparison of a fully automated immunoassay with a point-of-care testing method for B-type natriuretic peptide. Clin Chem 2005;51:1274–6.10.1373/clinchem.2005.048496Search in Google Scholar

28. Clerico A, Vittorini S, Passino C. Measurement of the pro-hormone of brain type natriuretic peptide (proBNP): methodological considerations and pathophysiological relevance. Clin Chem Lab Med 2011;49:1949–54.10.1515/CCLM.2011.686Search in Google Scholar

29. Collin-Chavagnac D, Aupetit JF, Barguil Y, Benoit MO, Bricca G, Cauliez B, et al. Inventory of the use of natriuretic peptides in France. Ann Biol Clin 2011;69:653–62.10.1684/abc.2011.0631Search in Google Scholar

30. Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH. National Academy of Clinical Biochemistry and IFCC committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: analytical issues for biomarkers of heart failure. Clin Biochem 2008;41:222–6.10.1016/j.clinbiochem.2007.07.001Search in Google Scholar

31. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003;334:233–9.10.1016/S0009-8981(03)00240-7Search in Google Scholar

32. Liang F, O’Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071–8.10.1016/j.jacc.2006.10.063Search in Google Scholar PubMed

33. Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS, Tolstaya AA, Koshkina EV, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007;53:866–73.10.1373/clinchem.2006.076141Search in Google Scholar PubMed

34. Cauliez B, Santos H, Bauer F, Basuyau JP, Nadolny A, Galpy G, et al. Cross-reactivity with endogenous proBNP from heart failure patients for three commercial BNP immunoassays. Clin Chim Acta 2012;413:337–8.10.1016/j.cca.2011.09.022Search in Google Scholar PubMed

35. Ala-Kopsala M, Magga J, Peuhkurinen K, Leipälä J, Ruskoaho H, Leppäluoto J, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B- type natriuretic peptides. Clin Chem 2004;50:1576–88.10.1373/clinchem.2004.032490Search in Google Scholar PubMed

36. Schellenberger U, O’Rear J, Guzzetta A, Jue RA, Protter AA, Pollitt NS. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys 2006;451:160–6.10.1016/j.abb.2006.03.028Search in Google Scholar PubMed

37. Seferian KR, Tamm NN, Semenov AG, Tolstaya AA, Koshkina EV, Krasnoselsky MI, et al. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem 2008;54:866–73.10.1373/clinchem.2007.100040Search in Google Scholar PubMed

38. Nishikimi T, Ikeda M, Takeda Y, Ishimitsu T, Shibasaki I, Fukuda H, et al. The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart 2012;98:152–61.10.1136/heartjnl-2011-300102Search in Google Scholar PubMed

39. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49:1733–9.10.1016/j.jacc.2006.10.081Search in Google Scholar PubMed

40. McDonald K, Dahlström U, Aspromonte N, Jourdain P, Maisel A, Mueller C, et al. B type-natriuretic peptide: application in the community. Congest Heart Fail 2008;14:12–6.10.1111/j.1751-7133.2008.tb00004.xSearch in Google Scholar PubMed

41. Felker GM, Hasselblad V, Hernandez AF, O’Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009;158:422–30.10.1016/j.ahj.2009.06.018Search in Google Scholar PubMed

42. Savarese G, Trimarco B, Dellegrottaglie S, Prastaro M, Gambardella F, Rengo G, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One 2013;8:e58287.10.1371/journal.pone.0058287Search in Google Scholar PubMed PubMed Central

43. Li P, Luo Y, Chen YM. B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials. Heart Lung Circ 2013;22:852–60.10.1016/j.hlc.2013.03.077Search in Google Scholar PubMed

44. Xin W, Lin Z, Mi S. Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev 2015;20:69–80.10.1007/s10741-014-9437-8Search in Google Scholar PubMed

45. Richards AM, Troughton RW. Use of natriuretic peptides to guide and monitor heart failure therapy. Clin Chem 2012;58:62–71.10.1373/clinchem.2011.165704Search in Google Scholar PubMed

46. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AH, Tate J, et al. Committee on standardization of markers of cardiac damage of the IFCC. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005;51:486–93.10.1373/clinchem.2004.044594Search in Google Scholar PubMed

47. Franzini M, Masotti S, Prontera C, Ripoli A, Passino C, Giovannini S, et al. Systematic difference between BNP immunoassays: comparison of methods using standard protocols and quality control materials. Clin Chim Acta 2013;424:287–91.10.1016/j.cca.2013.07.001Search in Google Scholar PubMed

48. Storti S, Prontera C, Emdin M, Passino C, Prati P, Fontani G, et al. Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: comparison with a point of care testing method. Clin Chem Lab Med 2004;42:1178–85.10.1515/CCLM.2004.238Search in Google Scholar PubMed


Supplemental Material

The online version of this article (DOI: 10.1515/cclm-2014-0592) offers supplementary material, available to authorized users.


Received: 2014-6-4
Accepted: 2015-3-10
Published Online: 2015-4-14
Published in Print: 2015-10-1

©2015 by De Gruyter

Downloaded on 29.3.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2014-0592/pdf
Scroll to top button